COVID-19 Vaccine Provider Weekly Updates

Stay Safe MN logo

COVID-19 Vaccine Provider Weekly Updates

View this as a webpage

Minnesota Department of Health

April 28, 2022


Pfizer-BioNTech submits application on booster doses for children 5-11 years old

On April 26, Pfizer and BioNTech submitted an application to the Food and Drug Administration (FDA) for emergency use authorization of a 10-mcg booster dose of the Pfizer-BioNTech COVID-19 vaccine for children 5-11 years of age. More information, including data from Pfizer’s Phase 2/3 clinical trial, can be found in BioNTech’s press release: Pfizer and BioNTech Submit Application for U.S. Emergency Use Authorization for a COVID-19 Vaccine Booster Dose in Children 5 Through 11 Years of Age.

Booster doses for children 5-11 years of age are not authorized by the FDA or recommended by the Center for Disease Control and Prevention (CDC) at this time. We will communicate any updates as soon as they become available.


Moderna submits applications for primary series in children 6 months to 6 years of age

Today, Moderna announced they have submitted applications to the FDA for emergency use authorization (EUA) of their COVID-19 vaccine in children 6 months up to 2 years of age and 2 years up to 6 years of age. Both requests are based on a 25-mcg two-dose primary series of their mRNA-1273 vaccine. For additional information, refer to Moderna’s April 28, press release: Moderna Files for Authorization of Its COVID-19 Vaccine in Young Children Six Months to Under Six Years of Age.

The FDA has not scheduled any meetings for the Vaccines and Related Biological Products Advisory Committee (VRBPAC) to discuss Moderna’s applications for an EUA in these age groups. We will relay more information in upcoming bulletins.


Updates to the interim clinical considerations

On April 21, the CDC updated the Interim Clinical Considerations for Use of COVID-19 Vaccines with guidance on second booster dose options and timing for those who are eligible, along with guidance for timing of first and second boosters after recent SARS CoV-2 infection. A new document, Clinical Considerations: Second COVID-19 Vaccine Booster Dose was also included and can be found in the reference materials section at the top of the page.

While this update focuses on a second booster, it is important clinicians keep in mind that the primary series with a booster provides the greatest benefit and protection against hospitalization and death. Providers should focus on getting all people up to date with their COVID-19 vaccinations.

Pfizer shelf-life extension and reporting waste

Please remember to check the information on the recent Pfizer shelf-life extension for gray and orange cap vaccine before reporting expired vials as wastage in MIIC. Refer to the April 21, 2022, COVID-19 Vaccine Provider Weekly Update for further information. This shelf-life extension does not apply to purple cap vaccine.

When submitting nonviable reports in MIIC, wastage amounts since time of last report can be combined by lot number and multiple lot numbers and products can be submitted in one report.

Find previous bulletins at COVID-19 Vaccine Provider Updates.